Market Cap$137m

Last Close $2.38

VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.

More VolitionRx content >

Investment summary

VolitionRx is a clinical diagnostics company with a different perspective on immunoassay technology for the detection and monitoring of severe diseases in both humans and companion animals. Unlike sequential organ failure assessment (SOFA), which requires multiple physiological measurements, VolitionRx’s proprietary Nu.Q neutrophil extracellular traps (NETs) immunoassay technology takes a more direct route in a largely stale and fragmented market. This ability to rapidly diagnose and monitor patients supports numerous clinical use cases across specialties and most immediately addresses sepsis, which has a c 25% mortality rate. VolitionRx aims to leverage its CE marking and demonstrate further proof of concept (PoC) in both preclinical and clinical settings to increase commercial activities in Europe in H222 and generate further clinical evidence to help support the application for FDA breakthrough device designation (BDD).

Content on VolitionRx
VolitionRx – Unravelling the web of NETs in sepsis
Healthcare | research Update | 15 August 2022
Executive interview: Volition – Q222 earnings
Healthcare | Edison TV | 15 August 2022
View more
Register to receive research on VolitionRx as it is published
Share price graph
Price performance
Actual 19.6 40.8 (26.3)
Relative* 13.5 36.5 (17.5)
52-week high/low US$3.5/US$1.4
*% relative to local index
Key management
Cameron Reynolds CEO
Terig Hughes CFO
Jake Micallef Chief Scientific Officer
Scott Powell Director of IR

You may also be interested in…